[ET Net News Agency, 23 June 2021] GenScript Biotech Corporation (01548) said its
subsidiary Legend Biotech has announced the establishment of a manufacturing facility in
Belgium, as part of a joint investment with Janssen Pharmaceutical NV, to expand global
manufacturing capacity of innovative cellular therapies.
Legend Biotech has a collaboration and licence agreement with Janssen Biotech, Inc. to
develop and commercialize ciltacabtagene autoleucel (cilta-cel), an investigational CAR-T
therapy currently under review by several health authorities around the world including
the United States and Europe for the treatment of patients with relapsed and refractory
multiple myeloma. (RC)